Anemia in the News

The American Society of Clinical Oncology (ASCO) has expressed concern over revised reimbursement policy for anemia drugs, repeatedly asking the Centers for Medicare & Medicaid Services (CMS) to reopen some provisions of the policy. ASCO contents areas of concern include:

• Stop treatment coverage for hemoglobin levels above 10 g/dL
• Allowance for one-time dose escalation of 25% for hypo-responders or non-responders
• Discontinued treatment if a patient’s hemoglobin level rises more than 1 g/dL within and two-week period

Last Updated: September 28, 2007